Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.42 |
| ▸ | GRM5 | P41594 | 5/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.42 |
| ▸ | GRM6 | O15303 | 5/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.38 |
| ▸ | GRM8 | O00222 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9666966 | 1.00 | GRM2 (0.42) | GRM2GRM5GRM1GRM6GRM3 | |
| SCHEMBL20533656 | 0.81 | GRM2 (0.39) | GRM2GRM5GRM1GRM6GRM3 | |
| SCHEMBL20533654 | 0.81 | GRM2 (0.39) | GRM2GRM5GRM1GRM6GRM3 | |
| SCHEMBL25907708 | 0.77 | GRM2 (0.42) | GRM2GRM5GRM1GRM6GRM3 | |
| Hydrochloric Acid SCHEMBL32674405 | 0.75 | NPSR1 (0.33) | — | |
| SCHEMBL15909554 | 0.70 | — | — | |
| SCHEMBL15428478 | 0.70 | — | — | |
| SCHEMBL11232712 | 0.70 | HSD11B1 (0.32) | — | |
| SCHEMBL5899735 | 0.70 | SLC6A2 (0.34) | GRM2GRM5GRM1 | |
| Hydrochloric Acid SCHEMBL25384535 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518885-B2 | Heterocyclic peptide ketoamides | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110053858-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| EP-2252310-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | Georgia Tech Research Corporation (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1692098-B1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009099416-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053858-A1 | HETEROCYCLIC PEPTIDE KETOAMIDES | CAPNS1, CAPN1, CAPN2 | GRM2 3000/4885GRM5 4281/4885GRM1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.